Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in ...

On September 13, 2024, the World Health Organization (WHO) announced that it added the first vaccine against monkeypox (mpox) to its ...

The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...

The World Health Organization (WHO) has authorized the MVA-BN vaccine as the first vaccine against mpox to be added to its ...

The WHO has approved the MVA-BN vaccine, manufactured by Bavarian Nordic A/S, as the first mpox (Monkeypox) vaccine.

In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

Lessons learned from the Covid pandemic have left the world in a much better position to tackle the current mpox epidemic ...

As mpox has now been found in the EU, the race for an effective vaccine has accelerated, with a study failure but increased vaccine production from Europe. The U.S. NIH just released top-line results ...

It added: Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) ...

A single dose of the Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) was 58% effective in protecting again mpox infection, according to a new study published in BMJ.

A recent Canadian trial revealed that the vaccine, originally developed for smallpox, offers 58% protection against Mpox ...